Becton, Dickinson (BDX) Inks Partnership Deal With CAPS

Becton, Dickinson and Company (NYSE:BDX) , popularly known as BD, recently announced a partnership with Central Admixture Pharmacy Services (CAPS). The agreement will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.

According to BD, “CAPS’ pre-filled anesthesia syringes are designed to prevent common compounding and labeling errors that occur in the operating room. These syringes are prepared in a controlled environment and undergo continuous testing for sterility, potency and endotoxin to meet strict new FDA quality control requirements.”

BD’s Intelliport System can automatically identify and utilize these syringes. The system is capable of providing real-time medication identification, dose measurement and patient drug allergy alerts at the point of injection. It is also capable of updating patient's electronic medical record (EMR) following medication administration.

The new collaboration reflects BD’s growing focus on patient safety and improving workflow. The earlier announced collaborations with Medtronic (NYSE:MDT) -- for the infusion set and Parker Institute for Cancer Immunotherapy -- in relation to the new Cell Sorter program are key growth drivers in our view.

Apart from partnerships, BD’s endeavor to develop innovative products is noteworthy. A plethora of FDA approvals in recent times has added products like Totalys MultiProcessor and Totalys SlidePrep instruments, FACSPresto system and FACSPresto CD4/Hb Cartridge and Vacutainer UltraTouch Push Button Blood Collection Set to the company’s portfolio.

Recently, BD announced the receipt of CE marking for its BD MAX Vaginal Panel -- a new in-vitro diagnostic (IVD) assay. The product expands BD’s reproductive and sexually transmitted Infections Portfolio.

Most recently, BD introduced its newest cell sorter -- the BD FACSMelody system -- which follows the launch of the company’s flow cytometers like BD Accuri C6 Plus and BD FACSCelesta systems.

Zacks Rank & Key Picks

BD carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the same space include Halyard Health (NYSE:HYH) and C.R. Bard (NYSE:BCR) . While Halyard Health sports a Zacks Rank #1 (Strong Buy), C.R. Bard has a Zacks Rank #2 (Buy).

MEDTRONIC (MDT): Free Stock Analysis Report

BARD C R INC (BCR): Free Stock Analysis Report

BECTON DICKINSO (BDX): Free Stock Analysis Report

HALYARD HEALTH (HYH): Free Stock Analysis Report

Original post

Zacks Investment Research